ReviewClinical reviews in allergy & immunology2020
Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still's Disease.
Review in Clinical reviews in allergy & immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Article
- Review
- Deep Immunophenotyping of Circulating T and B Cells in Relapsing Adult-Onset Still's Disease.Current issues in molecular biology · 2024Article
- Neutrophil extracellular traps and neutrophilic dermatosis: an update review.Cell death discovery · 2024Review
- Development and validation of the AF score for diagnosis of adult-onset Still's disease in fever of unknown origin.Journal of translational autoimmunity · 2023Article
- Clinical characteristics and outcome of elderly onset adult-onset Still's disease: A 10-year retrospective study.Journal of translational autoimmunity · 2023Article
- Elevated White Blood Cell Count and Lactate Dehydrogenase Levels Are Important Markers for Diagnosing Relapse of Adult-onset Still's Disease under Tocilizumab Use.Internal medicine (Tokyo, Japan) · 2022Article
- Refractory adult-onset Still's disease complicated with monoclonal gammopathy of undetermined significance: A case report.Medicine · 2022Article
- Adult-Onset Still's Disease With Severe Hyperferritinemia and the Asian Salmon-Pink Rash: A Case Report.Cureus · 2022Article
- New insights on multigenic autoinflammatory diseases.Therapeutic advances in musculoskeletal disease · 2022Review
- Bibliometrics and Visual Analysis of Adult-onset Still Disease (1976-2020).Frontiers in public health · 2022Article
- Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.Frontiers in medicine · 2022Review
- Adult-onset Still's disease after environmental exposure while working in Africa.BMJ case reports · 2021Article
- Recurrent deep venous thromboses in a patient with adult-onset Still's disease.BMJ case reports · 2021Article
- Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.Clinical reviews in allergy & immunology · 2021Review
- An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.Journal of immunology research · 2021Review
- Clinical relevance for circulating cold-inducible RNA-binding protein (CIRP) in patients with adult-onset Still's disease.PloS one · 2021Article
- Future perspective: high-throughput construction of new ultrasensitive cytokine and virion liquid chips for high-throughput screening (HTS) of anti-inflammatory drugs or clinical diagnosis and treatment of inflammatory diseases.Analytical and bioanalytical chemistry · 2020Article
- Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.Journal of autoimmunity · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Adult-onset Still's disease (AOSD) is a rare multisystem autoinflammatory disorder of unknown etiology. AOSD is generally characterized by high spiking fever, arthralgia or arthritis, skin rash, leukocytosis, and hyperferritinemia. Traditionally, AOSD has been treated with non-steroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants. An increasing number of studies have shown that proinflammatory cytokines, such as interleukin-1β, -18, -6, and tumor necrosis factor-α, play key roles in AOSD and may serve as therapeutic targets. In the current review, we provided insights into the roles of these cytokines in the pathogenesis of AOSD and also provided a commentary on the clinical studies of biologic therapy against AOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.